How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43,660 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. OUTREACH: Urine Analysis and Antihypertensive Treatment

assessment, intervention, short-term and long-term outcome visits). The study will fill in an important gap in knowledge on management of blood pressure in non-adherent hypertensive patients beyond the initial diagnostic step. It will also inform the development of a cost-effective model for the management of non-adherence in chronic disorders that require long-term drug therapy. Condition or disease Intervention/treatment Phase Hypertension Adherence, Medication Other: HPLC-MS/MS-guided intervention (...) Other: Standard care Not Applicable Detailed Description: Non-adherence to antihypertensive treatment is one of the leading causes of suboptimal blood pressure control and translates into increased risk of cardiovascular morbidity and mortality. Currently, there is no effective intervention for therapeutic non-adherence. An ultra-sensitive and highly specific biochemical assay has been developed to detect urinary biomarkers of antihypertensive treatment. The high performance liquid chromatography

2017 Clinical Trials

82. Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

also has a lot of blood vessel remodeling with their condition, they are more likely to have poor results with medical treatment for hypertension. The researchers examine the impact of different classes of drugs that doctors use to treat high blood pressure (hypertension) on blood vessel remodeling. Some drugs that doctors prescribe for their patients contain a "sulfhydryl group" (a sulfur atom bonded to a hydrogen atom). Drugs that have the sulfhydryl group may reduce blood vessel remodeling more (...) <120/80 mmHg Hypertensive ≥140/90 mmHg and <160/110 mmHg HbA1C of <6.5% Women are post-menopausal and not taking hormone replacement therapy, or have normal cycles and are tested in the early follicular phase Subjects may or may not be taking one doctor-prescribed drug to lower blood pressure (e.g. diuretic, ACE inhibitor). Must be able to stop physician-prescribed antihypertensive drug for the duration of the subject's participation in the study (with the approval of their personal physician

2017 Clinical Trials

83. Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment

minimal sedation as an early antihypertensive treatment for spontaneous intracerebral hemorrhage. The analgesia-first minimal sedation strategy relies on the remifentanil-mediated alleviation of pain-induced stress response and the antisympathetic activity of dexmedetomidine to restore the elevated blood pressure to normal level in patients with spontaneous intracerebral hemorrhage. This strategy allows rapid stabilization of blood pressure, and its use as a pre-treatment for patients on mechanical (...) 90% ICH patients have increased blood pressure (BP) that usually occurs immediately after disease onset. BP elevation in the acute phase of ICH is associated with poor prognosis, and its mechanism of action includes the local increase of initial hemorrhage, early hematoma expansion at hemorrhagic sites, the increased risk of early recurrent hemorrhage, serious cerebral edema, and recurrent stroke, this affects the most within the few hours following the onset of the disease. The current American

2017 Clinical Trials

84. Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

: Interventional (Clinical Trial) Estimated Enrollment : 280 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile. Actual Study Start Date : December 2015 Estimated (...) , 2017 Last Update Posted : July 14, 2017 See Sponsor: Cvie Therapeutics Ltd. Information provided by (Responsible Party): Cvie Therapeutics Ltd. Study Details Study Description Go to Brief Summary: The principal aim of the study is to demonstrate that Rostafuroxin is able to induce a more pronounced reduction of arterial blood pressure respect to Losartan, in hypertensive patients carrying at least one of the pre-specified gene mutations. In previous studies has been demonstrated

2017 Clinical Trials

85. Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial. Full Text available with Trip Pro

with mild primary hypertension, 10-year risk of cardiovascular diseases (CVDs) lower than 20% and no history of CVDs were recruited and randomly allocated to two groups. EBI plus general counselling was provided to the intervention group and general counselling alone to the control group. EBI counselling included information on the 10-year CVD risk and treatment benefit in terms of absolute risk reduction estimated for each individual and information on average side effects and costs of antihypertensive (...) Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial. To evaluate whether evidence-based, individualised (EBI) counselling regarding hypertension and the treatment would affect medication use in insured patients with mild hypertension in China.We conducted a parallel-group, randomised controlled trial in two primary care centres in Shenzhen, a metropolitan city in China. Patients

2019 BMJ evidence-based medicine Controlled trial quality: predicted high

86. Guidelines for blood pressure measurement, diagnosis, and assessment of risk of pediatric hypertension

(Grade C) 1. Medical history: Symptoms Of hypertension Of an underlying disorder* Medical history For underlying cause of hypertension,* including neonatal history Identifyothercardiovascularriskfactorsincludinginactivity,smoking, and dietary factors Family history 2. Patient physical examination: Height, weight, and body mass index Vital signs, including upper and lower limb BP measurements Evaluation for signs of end-organ damage Fundi, cardiovascular, and neurologic systems Evaluation (...) for underlying cause of hypertension* BP, blood pressure. *Systems to review include renal, cardiovascular, endocrine, and neuro- logic, as well as medications/drugs and sleep disorders. 592 Canadian Journal of Cardiology Volume 32 2016ChildrenwithBPthe95thpercentileforage,sex,andheight can have evidence of target organ damage. 25-31 Additionally, elevatedBPinchildhoodpredictshypertensioninadulthood,as demonstrated in a recentmeta-regression analysis. 4 Staging is important because children with stage 2

2016 CPG Infobase

87. Guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

[oscillometric] measurement should be used). 3. Four approaches can be used to assess BP: i. For non-AOBP, an SBP 140 mm Hg or a diastolic BP (DBP) 90 mm Hg is high, and an SBP between 130 and 139 mm Hg and/or a DBP between 85 and 89 mm Hg is high-normal (Grade C). ii. AOBP is the preferred method of performing in-of?ce BP measurement (Grade D; new recommendation). When using AOBP (see the section on Recommended Technique for Automated Of?ce Blood Pressure in Supplemental Table S2), a displayed mean SBP (...) method (Grade D). Patients can be diagnosed with hypertension according to the thresholds outlined in section I, recommendation 3. Figure 1. Hypertension diagnostic algorithm. ABPM, ambulatory BP measurement; AOBP, automated of?ce BP; BP, blood pressure. 574 Canadian Journal of Cardiology Volume 32 2016ii. Home BP monitoring is recommended if ambulatory BP monitoring is not tolerated, not readily available, or because of patient preference (Grade D). Patients can be diagnosed with hypertension

2016 CPG Infobase

88. Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)

) by the general practitioners investigators of the CIC-P. The main purpose of the study is to determine the factors associated with the rate of patients remaining normotensive one year after stopping their antihypertensive monotherapy or low dose dual therapy: white coat hypertension primary diagnosis by home blood pressure measurements (HBPM) /ambulatory blood pressure measurements (ABPM) /clinical measure initial blood pressure level compliance therapeutic class versus others age gender weight variation (...) studies before adding more. Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02268071 Recruitment Status : Recruiting First Posted

2014 Clinical Trials

89. Excessive daytime sleepiness and adherence to antihypertensive medications among Blacks: analysis of the counseling African Americans to control hypertension (CAATCH) trial. Full Text available with Trip Pro

the Counseling African-Americans to Control Hypertension (CAATCH) trial.A total of 1,058 hypertensive blacks (average age 57±12 years) participated in CAATCH, a randomized controlled trial evaluating the effectiveness of a multilevel intervention for participants who receive care from community health centers in New York City. Data analyzed in this study included baseline sociodemographics, medical history, EDS, and medication adherence. We used the Epworth Sleepiness Scale, with a cutoff score of ≥10 (...) , to define EDS. Medication adherence was measured using an abbreviated Morisky Medication Adherence scale, with a score >0 indicating nonadherence.Of the sample, 71% were female, 72% received at least a high school education, 51% reported a history of smoking, and 33% had a history of alcohol consumption. Overall, 27% of the participants exhibited EDS, and 44% of those who exhibited EDS were classified as adherent to prescribed antihypertensive medications. Multivariable logistic regression analysis

2014 Patient preference and adherence Controlled trial quality: uncertain

90. Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record (...) managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients The safety and scientific

2012 Clinical Trials

91. A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension - Full Text View - ClinicalTrials.gov Hide glossary (...) the written informed consent Subjects aged 20 to 75 years Essential hypertension subjects who are measured more 90mmHg, less than 114mmHg of sitting diastolic blood pressure (SiDBP) at baseline(day 0). Subjects who considered to understand this study , be cooperative, and able to be followed-up whole of the study period. Exclusion Criteria: Severe hypertension patients; more 115mmHg of SiDBP and/or more 185 mmHg of Sitting systolic blood pressure (SiSBP) Patients with secondary hypertension Patients

2012 Clinical Trials

92. A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting (...) registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension (fimasartan) The safety and scientific validity of this study is the responsibility

2012 Clinical Trials

93. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. (Abstract)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use (...) eligibility criteria at the final screening visit were stratified by local serum potassium measurement (4·3 to <4·7 mmol/L vs 4·7 to 5·1 mmol/L) and history of diabetes. Participants were randomly assigned (1:1) with an interactive web response system to receive either placebo or patiromer (8·4 g once daily), in addition to open-label spironolactone (starting at 25 mg once daily) and their baseline blood pressure medications. Participants, the study team that administered treatments and measured blood

2019 Lancet

94. The Risk Factors That Predict Chronic Hypertension After Delivery in Women With a History of Hypertensive Disorders of Pregnancy. Full Text available with Trip Pro

demonstrated that the clinical risk factors, that is early onset hypertension with end-organ dysfunction, smoking, and higher prepregnancy BMI, were significant independent predictors of chronic hypertension in women after delivery. Identification of risk factors allowed us to narrow the subject field for monitoring and managing high blood pressure in the postpartum period. (...) The Risk Factors That Predict Chronic Hypertension After Delivery in Women With a History of Hypertensive Disorders of Pregnancy. Hypertensive disorders of pregnancy (HDP) is one of the most important lethal complications in pregnant mothers. It is also associated with the subsequent development of chronic hypertension. The objective of this study was to identify the clinical risk factors of postpartum chronic hypertension in women diagnosed with HDP.Six hundred patients as HDP, who diagnosed

2015 Medicine

95. Guideline for the diagnosis and management of hypertension in adults — 2016

Foundation of Australia has updated the Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults (updated December 2010). Main recommendations For patients at low absolute cardiovascular disease risk with persistent blood pressure (BP) ≥ 160/100 mmHg, start antihypertensive therapy. The decision to treat at lower BP levels should consider absolute cardiovascular disease risk and/or evidence of end-organ damage, together with accurate BP assessment. For patients (...) ). A 2015 trial comparing lower with higher blood pressure targets in selected high cardiovascular risk populations found improved cardiovascular outcomes and reduced mortality, with an increase in some treatment-related adverse events. Blood pressure (BP) is an important common modifiable risk factor for cardiovascular disease. In 2014–15, 6 million adult Australians were hypertensive (BP ≥ 140/90 mmHg) or were taking BP-lowering medication. Hypertension is more common in those with lower household

2016 MJA Clinical Guidelines

96. First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension

kidney disease, and heart failure. The objective of this study is to assess the effectiveness and safety of a catheter-based system to ablate the carotid body and reduce blood pressure (BP) in patients with resistant hypertension and to confirm sustainability of the treatment benefits long-term as seen following surgical CB removal. Condition or disease Intervention/treatment Phase Hypertension,Essential Device: Catheter-Based Carotid Body Ablation Not Applicable Study Design Go to Layout table (...) of major adverse events defined as all-causes of death, hospitalization for hypertensive crisis not related to confirmed non-adherence with anti-hypertensive medications, and any device or procedure-related serious adverse event. Mean reduction in 24-hour ambulatory systolic and diastolic blood pressure [ Time Frame: Baseline versus six months post-procedure ] Secondary Outcome Measures : Composite rate of major adverse events [ Time Frame: At 6, 12, 18, and 24 months post-procedure ] Safety assessed

2017 Clinical Trials

97. Evaluation of the Relationship between Serum 25-Hydroxy Vitamin D and Hypertension in Hamadan, Iran-A Case Control Study Full Text available with Trip Pro

Evaluation of the Relationship between Serum 25-Hydroxy Vitamin D and Hypertension in Hamadan, Iran-A Case Control Study Hypertension or high blood pressure is one of the main reasons of fatality in the world. The role of vitamin D in developing hypertension has not been proved yet. Some studies have shown positive correlation between low serum vitamin D level and hypertension. Due to this fact, recognising hypertension risk factors such as potential impact of low serum vitamin D level seems (...) to be required.This study was conducted to evaluate potential impact of serum vitamin D level on hypertension.This case-control study had 188 subjects including 55 cases suffering from hypertension and 133 controls with normal blood pressure in Hamadan, Iran. After taking the medical history and physical examination, 5 cc of their blood was taken to measure their serum 25-Hydroxyvitamin D [25(OH)D] level through ELISA test. Data analysis was done by version 16.0 of SPSS software and used independent sample t-test

2017 Journal of clinical and diagnostic research : JCDR

98. A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension

for at least 4 weeks, with mean BP ≥150/90 mmHg based on 3 office blood pressure measurements, or ASBP≥135 mmHg based on 24 hr blood pressure monitoring; Heart beats at rest ≥70 bpm Confirmed diagnosis of primary hypertension or CKD hypertension; Main renal artery, with or without accessary renal arteries; Agrees to take part in the trial and signs the written, informed consent. Exclusion Criteria: Pregnant or plan to become pregnant, or Breastfeeding; Renal artery abnormalities that are inappropriate (...) for the procedure (renal stenosis ≥50%, aneurysm, renal artery diameter <4mm or length<20mm) ; Only one kidney or kidney transplant recipient Prior renal artery interventional procedures or prior RDN treatment; Any conditions affecting accuracy of blood pressure measurement, such as diameter of upper arm too large for the cuff or severe arrhythmia; Secondary hypertension other than CKD hypertension; Pseudohypertension; History of orthostatic hypotension; Average systolic blood pressure (ASBP) <135mmHg based

2017 Clinical Trials

99. Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2017 Clinical Trials

100. Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

Genomics SA Information provided by (Responsible Party): Quantum Genomics SA Study Details Study Description Go to Brief Summary: Essential hypertension (HTN) is a disease that affects approximately 1 billion individuals worldwide. Despite the availability of effective and safe anti-hypertensive drugs, 65% of subjects diagnosed with HTN do not have their blood pressure (BP) controlled (<140/90 mmHg). The overall incidence of resistant HTN, (defined as requiring 3 or more anti-hypertensive drugs (...) of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily [QD]) on blood pressure (BP) over 8 weeks in hypertensive overweight/obese subjects of multiple races/ethnicities. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 256 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 2, Open-Label, Dose

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>